VERIFIEDET Finance·13 May 2026neutral

Zydus Lifesciences close to buying US oncology drug maker for $100 to 150 million: Sources

AI Summary

·Zydus Lifesciences is nearing a deal to acquire a US-based oncology drug maker.
·The potential acquisition is valued between $100 million and $150 million.
·The move aims to establish Zydus's distribution network for anti-cancer drugs in the US and includes the target's biologic drug pipeline.